Cipla confident of growth in next two years.

Feb 09, 2021 | 1 min Read

Cipla was among the first companies in India to launch a generic version of remdisivir ,developed by U.S based Gilead Sciences ,and as of september had sold more than 300,000 vials across India. Its consolidated net profit more than doubled during the three months ended Dec. 31, helped by higher demand for other drugs across its portfolio. With Indian Pharma market expected to grow pharmaceuticals are one of the top attractive sectors for foreign investment in India.